top of page

Novartis’ HR+/HER2- advanced breast cancer trial gives superior progression-free survival

Results from the pivotal Phase III monaleesa-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS) compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (median PFS, 95% CI (19.3 months – not reached) vs. 14.7 months (13.0 – 16.5 months); HR=0.556; p=0.00000329).

Click on this link for more information.

Source:http://www.europeanpharmaceuticalreview.com/44506/news/industry-news/novartis-breast-cancer-survival/

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page